| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Objectives. The role of circulating tumor cells and nucleic acids in prognostication in non-small cell lung cancer patients is controversial, but may be better defined with advancing technologies of detection of such cells or free tumor DNA with higher precision, and improved clinical-pathological correlations. Biomarker measurements of minimal systemic disease (MSD) have the potential to monitor the molecular status of tumors without invasive tumor biopsy at the time of treatment selection. Patients: This is a pilot study to test for the presence of the minimal systemic disease in 69 lung cancer patients undergoing curative surgery. Methods: We used real-time RT-PCR method for absolute gene expression quantification of carcinoembryonic antigen (CEA), epidermal growth factor receptor 1 (EGFR1), palate, lung and nasal epithelium associated protein (LUNX) and hepatocyte growth factor receptor (c-met) in peripheral blood, blood from pulmonary veins and samples of bone marrow. Conclusions: These pilot study shows that the MSD detection in lung cancer is technically possible and highly specific and sensitive markers for the monitoring of MSD are available. The clinical relevance of this minimal tumor cell dissemination is under permanent debate. It is our hope that validation of postoperative persistence or re-appearance of tumor cells may help to identify patients in need of adjuvant systemic therapy. Optimalization of the panel of specific tumor markers and evaluation of their validity in monitoring of minimal systemic disease in lung cancer patients need to be investigated in further studies.
- Objectives. The role of circulating tumor cells and nucleic acids in prognostication in non-small cell lung cancer patients is controversial, but may be better defined with advancing technologies of detection of such cells or free tumor DNA with higher precision, and improved clinical-pathological correlations. Biomarker measurements of minimal systemic disease (MSD) have the potential to monitor the molecular status of tumors without invasive tumor biopsy at the time of treatment selection. Patients: This is a pilot study to test for the presence of the minimal systemic disease in 69 lung cancer patients undergoing curative surgery. Methods: We used real-time RT-PCR method for absolute gene expression quantification of carcinoembryonic antigen (CEA), epidermal growth factor receptor 1 (EGFR1), palate, lung and nasal epithelium associated protein (LUNX) and hepatocyte growth factor receptor (c-met) in peripheral blood, blood from pulmonary veins and samples of bone marrow. Conclusions: These pilot study shows that the MSD detection in lung cancer is technically possible and highly specific and sensitive markers for the monitoring of MSD are available. The clinical relevance of this minimal tumor cell dissemination is under permanent debate. It is our hope that validation of postoperative persistence or re-appearance of tumor cells may help to identify patients in need of adjuvant systemic therapy. Optimalization of the panel of specific tumor markers and evaluation of their validity in monitoring of minimal systemic disease in lung cancer patients need to be investigated in further studies. (en)
|
| Title
| - Different markers for minimal systemic disease detection in lung cancer patients.
- Different markers for minimal systemic disease detection in lung cancer patients. (en)
|
| skos:prefLabel
| - Different markers for minimal systemic disease detection in lung cancer patients.
- Different markers for minimal systemic disease detection in lung cancer patients. (en)
|
| skos:notation
| - RIV/61989592:15110/11:33119771!RIV12-MZ0-15110___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/11:33119771
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - lung cancer; minimal systemic disease; markers (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...iv/tvurceVysledku
| - KOLÁŘ, Zdeněk
- CHUDÁČEK, Josef
- HAJDÚCH, Marián
- Janásková, T.
- KLEIN, Jiří
- SKALICKÝ, Pavel
- SROVNAL, Josef
- ŠKARDA, Jozef
|
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)